Qui sommes-nous ? About us
L'ANSM en bref
About us
Nos engagements
Nos missions
Notre périmètre
Notre organisation
Déontologie et transparence
Publications institutionnelles
Publications scientifiques
Rejoignez-nous !
Notre agenda
 
Bulletin officiel des actes, décisions et avis
Décisions institutionnelles
Décisions liées aux médicaments
Décisions liées aux produits sanguins et autres produits biologiques
Décisions liées aux médicaments dérivés du plasma
Décisions liées aux dispositifs médicaux et dispositifs médicaux de diagnostic in vitro
Injonctions
Décisions de police sanitaire
Sanctions financières
Avis
 
Disponibilité des produits de santé
Médicaments
Dispositifs médicaux et dispositifs médicaux de diagnostic in vitro
 
Vos démarches
Industriel
Organismes notifiés
Professionnel de santé
Patient
Chercheur

Our organisation

A+ A-
> Consultez la version française

Two bodies are tasked with ANSM’s governance: a Management Board, and a Scientific Board.

In addition, since 2019, the Agency’s policy of openness to civil society has resulted in healthcare system users being systematically involved in our consultative bodies of expertise. We are convinced of the need to work alongside patients and healthcare professionals to ensure that our action addresses the challenges that they face on a daily basis.

For this reason, our decisions are based on the opinions of several consultative committees, in which the expertise of representatives of civil society, their perspective, and their vision of the health sector allow objective and informed decision-making.
 

Interface Committees


A direct interface between the ANSM and stakeholders (manufacturers, patient associations, healthcare professionals) is ensured via “interface committees”.

These committees enable regular and constructive dialogue on general matters, in accordance with Agency’s rules of transparency.

Created and constituted by decision of the Director General, they bring together both stakeholder and Agency representatives:
  • The Interface Committee working with patient or healthcare system user associations involved in the health products sector.
  • The Medical Interface Committee with National Professional Councils (CNP), including representatives from the Federation of Medical Specialties (FSM) and the College of General Practitioners (CMG). Its objective is to promote the organisation and fluidity of exchanges between the Agency and the CNP.
  • The Interface Committee working with pharmacist representatives: National Board of Pharmacists and the main pharmaceutical unions, in both the retail sector (FSPF and USPO) and hospital sector (SNPHPU, SYNPREFH). Its objective is to encourage dialogue, to give pharmacists the opportunity to contribute to the ANSM's activities and missions, and to better understand and take into consideration the expectations of pharmacists.
  • Two interface committees with representatives of the pharmaceutical industries, and their associated working groups:
    • Interface Committee working with medicinal product industry representatives;
    • Interface Committee working with medical device and in vitro diagnostic medical device industry representatives;
  • The “Innovation Support” Interface Committee. Its aim is to promote more regular exchanges between the Agency and stakeholders on the ground on innovation support mechanisms for all healthcare products.